OM:BIOA BBiotechs
BioArctic (OM:BIOA B) Is Up 18.7% After Novartis Partnership and Strong Earnings Turnaround Has The Bull Case Changed?
In late August 2025, BioArctic reported strong second-quarter and half-year results, with sales rising to SEK 392.12 million and SEK 1.68 billion respectively, and moved from a net loss to solid profitability on both periods versus the previous year.
Novartis also announced a collaboration and license option agreement with BioArctic for its BrainTransporter technology, offering an upfront US$30 million payment and the potential for further milestone and royalty payments if development...